
COVID-19: Pivoting to recovery
Contact us/ [email protected]
COVID-19: pivoting to recovery
As the COVID-19 pandemic continues and the vaccine rollout proceeds at varying paces across the globe, organisations find themselves in different and sometimes multiple stages of the crisis management lifecycle. Using Control Risks’ Readiness, Response and Recovery methodology, we are helping clients navigate their way through the crisis by shaping responses that target rapid commercial recovery and factor in longer-term scenarios. We provide critical insights and advice on how to manage fast-moving information cycles and adapt your existing crisis recovery measures to new developments. Remaining flexible, agile, forward-thinking and empathetic are all essential for a successful outcome.

Recovery
RiskMap 2021: Missing the rebound
: With the arrival of COVID-19 vaccines those businesses that refuse to embrace risk in 2021 are in danger of failing to capitalise on the recovery. Economies most heavily affected by COVID will rebound fastest, with European growth set to outstrip China for the first time in decades. Many businesses will need to transform their business models in even more significant ways than they already have. Companies’ competitiveness will be defined by their values, as much as by productivity and profits.

Recovery
COVID-19 vaccine diplomacy – from nationalism to friendship
Vaccine rollouts have begun quickly in some countries while others wait. We examine the divergent impacts on diplomatic relations between states prioritising domestic vaccination and others sharing their doses overseas.

Recovery
RiskMap2021: A world with long COVID
A year of uneven recovery lies ahead as vaccine rollouts create a world of haves and have nots. Competition will be fierce between nations and within them, and budgets will creak under the weight of their new debt, pushing some countries to the wall, or prolonging austerity. The relationships between state and business and between society and business will be critical for companies. If 2021 does not mark the end of the pandemic, it will be the year that determines what is left when the worst is over.

Recovery
Navigating third-party risks in pharma and life sciences
: Compliance leads at pharmaceutical and life sciences companies have one of the least navigable jobs in our field. The complexity and uncertainty surrounding the COVID-19 pandemic has presented an array of operational issues with third-party compliance.

Response
Rethinking your global corporate response to social unrest
COVID has both intensified and accelerated the threat posed by unrest to business, from both a likelihood and impact standpoint. Key to successfully navigating the way forward is to apply the same holistic, multi-disciplinary approach we advocate for managing all forms of crisis. It’s time to embrace a longer-term view and mindset that acknowledges unrest as the “new norm” – not only in the US, but globally. Read more to uncover the five steps companies can take to prepare for social unrest wherever it occurs.

Recovery
Investing during and after COVID-19
The investment climate created by the COVID-19 pandemic has demanded strong stomachs as fortune has drained from some sectors overnight and seen others flush with opportunity. Political and policy uncertainties, and heightened societal activism, require private market investors to be acutely sensitive to the profile and timing of their investment decisions.

Coverage of COVID-19 on CORE
Existing subscribers to CORE can access regular updates about COVID-19 through the platform. In addition, subscribers can benefit from a direct link to our experts to discuss topics related COVID-19 and their unique circumstances via CORE+ Analyst Access hours.
Latest Situation Update
The decisions companies need to make in response to mass vaccination and the easing of lockdowns are complex.
Webinar
What does COVID-19 mean for your active crisis management programmes and what lies ahead for business?
COVID-19: Business Resumption
From crisis response to business resumption, optimise your approach to resumption planning with unique insights and tools.
Everbridge Critical Event Management support
Control Risks is supporting organisations throughout the pandemic. Through our partnership with Everbridge, we are combining technology and risk intelligence solutions with crisis management expertise.
Contact/ Our Experts
COVID-19 videos
Handling the information overload
Legal and compliance – 8 considerations
Receive dedicated COVID-19 insights
Related articles


Business travel – cleared for take-off?

Managing remote terminations during COVID-19

COVID-19: Crisis management and threat management in a new era

COVID-19 “In-Flight” incident reviews - A prudent pause on the road to resumption

COVID-19: Business resumption framework

COVID-19: Insider risks to recovery and resilience

COVID-19: Taking the first steps to Recovery

Internal Investigations – Getting the basics right

COVID-19: What to focus on now, what to focus on next
COVID-19: Global Monitoring and Information Services
Control Risks’ Global Monitoring Information Services supports clients’ decision-making in response to the ongoing COVID-19 crisis. Services include trigger monitoring, email alerts, executive briefings and regional outlooks to ensure you can remain agile and empathetic as the situation evolves.

Leadership in the COVID-19 crisis

New global scenarios for COVID-19
Steering your business through the COVID-19 crisis
As the COVID-19 outbreak evolves so do our client’s concerns. With our global expertise in helping organisations through epidemic and pandemic scenarios, Control Risks’ solutions can help your organisation to be ready, respond, and recover.

COVID-19: The impact on workers in global supply chains

Crisis management in the midst of an emergent outbreak

Preparing for natural disasters in the time of COVID-19

Back to work the risks for business of returning employees to the workplace
Remote investigations during COVID-19
In this roundtable discussion, Andrew Weissmann of Jenner & Block joins Brian Mich, Mavis Tan, Michael Zimmern and Ching Liu discuss conducting remote investigations during COVID-19.
